174 related articles for article (PubMed ID: 36495466)
1. TIPE1 inhibits the growth of Ewing's sarcoma cells by suppressing Wnt/β-catenin signaling.
Wang Z; Sun L; Liu S; Jiang H
Clin Transl Oncol; 2023 May; 25(5):1332-1339. PubMed ID: 36495466
[TBL] [Abstract][Full Text] [Related]
2. miR-185 suppresses progression of Ewing's sarcoma via inhibiting the PI3K/AKT and Wnt/β-catenin pathways.
Zhang S; Li D; Jiao GJ; Wang HL; Yan TB
Onco Targets Ther; 2018; 11():7967-7977. PubMed ID: 30519038
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
4. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.
Tanaka M; Yamazaki Y; Kanno Y; Igarashi K; Aisaki K; Kanno J; Nakamura T
J Clin Invest; 2014 Jul; 124(7):3061-74. PubMed ID: 24911143
[TBL] [Abstract][Full Text] [Related]
5. LncRNA TUG1 promotes Ewing's sarcoma cell proliferation, migration, and invasion via the miR-199a-3p-MSI2 signaling pathway.
Li H; Huang F; Liu XQ; Liu HC; Dai M; Zeng J
Neoplasma; 2021 May; 68(3):590-601. PubMed ID: 33780263
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.
Knowles HJ; Schaefer KL; Dirksen U; Athanasou NA
BMC Cancer; 2010 Jul; 10():372. PubMed ID: 20637078
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
Lu Q; Lu M; Li D; Zhang S
Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
[TBL] [Abstract][Full Text] [Related]
8. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
10. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
13. Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma.
Greve B; Sheikh-Mounessi F; Kemper B; Ernst I; Götte M; Eich HT
Strahlenther Onkol; 2012 Nov; 188(11):1038-47. PubMed ID: 23053158
[TBL] [Abstract][Full Text] [Related]
14. Picropodophyllin inhibits the growth of Ewing's sarcoma cells through the insulin‑like growth factor‑1 receptor/Akt signaling pathway.
Wu YT; Wang BJ; Miao SW; Gao JJ
Mol Med Rep; 2015 Nov; 12(5):7045-50. PubMed ID: 26323364
[TBL] [Abstract][Full Text] [Related]
15. RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.
Arora S; Gonzales IM; Hagelstrom RT; Beaudry C; Choudhary A; Sima C; Tibes R; Mousses S; Azorsa DO
Mol Cancer; 2010 Aug; 9():218. PubMed ID: 20718987
[TBL] [Abstract][Full Text] [Related]
16. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
18. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
19. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.
Landuzzi L; De Giovanni C; Nicoletti G; Rossi I; Ricci C; Astolfi A; Scopece L; Scotlandi K; Serra M; Bagnara GP; Nanni P; Lollini PL
Am J Pathol; 2000 Dec; 157(6):2123-31. PubMed ID: 11106584
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
